<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742453</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2018-2268</org_study_id>
    <nct_id>NCT03742453</nct_id>
  </id_info>
  <brief_title>Evaluation of Diagnostic Accuracy of CEUS for HCC Diagnosis</brief_title>
  <official_title>Evaluation of Diagnostic Accuracy of Contrast-enhanced Ultrasound (CEUS) and Gadoxetic Acid-enhanced Liver MRI for Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bracco Corporate</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the diagnostic accuracy of Contrast-enhanced ultrasound (CEUS) for
      diagnosing hepatocellular carcinoma (HCC) with that of gadoxetic acid-enhanced liver magnetic
      resonance imaging (MRI) using non-invasive diagnostic criteria (American Association for the
      Study of Liver Disease (AASLD or Liver Imaging Reporting and Data System (LI-RADS) v2018 and
      Korean Liver Cancer Study Group- National Cancer Center Korea (KLCSG-NCC) v2018).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance of CEUS for diagnosing HCC</measure>
    <time_frame>3 months after CEUS</time_frame>
    <description>accuracy, sensitivity, specificity of CEUS for HCC diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of gadoxetic-acid liver MRI for diagnosing HCC using LI-RADSv2018</measure>
    <time_frame>3 months after MRI</time_frame>
    <description>accuracy, sensitivity, specificity of MRI using LI-RADS v2018 for HCC diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of gadoxetic-acid liver MRI for diagnosing HCC using KLCSG-NCC guidelinev2018</measure>
    <time_frame>3 months after MRI</time_frame>
    <description>accuracy, sensitivity, specificity of MRI using KLCSG-NCC guideline v2018 for HCC diagnosis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">107</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Hepatic nodule group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group meets eligibility criteria, and undergo contrast-enhanced ultrasound (CEUS) and scheduled gadoxetic acid MRI (gadoxetic acid-enhanced liver MRI; EOB-MRI; Gd-EOB-MRI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>contrast-enhanced ultrasound</intervention_name>
    <description>CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.</description>
    <arm_group_label>Hepatic nodule group</arm_group_label>
    <other_name>CEUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>EOB-MRI</intervention_name>
    <description>EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.</description>
    <arm_group_label>Hepatic nodule group</arm_group_label>
    <other_name>gadoxetic acid MRI</other_name>
    <other_name>Gd-EOB-MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High risk group of developing HCC

          -  hepatic nodule equal to or larger than 1cm on ultrasound or computed tomography (CT)

          -  newly detected nodule (equal to or larger than 1cm, at least 2cm distance from
             radiofrequency ablation (RFA) site or resection margin) in patients with history of
             hepatic resection or RFA for HCC AND in remission more than a year

          -  scheduled for gadoxetic acid-enhanced liver MRI

          -  signed informed consent

        Exclusion Criteria:

          -  hypersensitivity for ultrasound contrast media

          -  pregnancy

          -  history of recent treatment for HCC in a year

          -  standard of reference is not available

          -  severe cardiopulmonary disease (right to left shunt, severe pulmonary hypertension,
             uncontrolled hypertension, etc)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Hee Lee, RN</last_name>
    <phone>82-2-2072-4177</phone>
    <email>redlion55@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Hee Lee, RN</last_name>
      <phone>82-2-2072-4177</phone>
      <email>redlion55@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Jeong Hee Yoon, MD</last_name>
      <phone>82-2-2072-2584</phone>
      <email>jhjhry@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeong Min Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CEUS</keyword>
  <keyword>gadoxetic acid</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

